5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone
5-Fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone
CAS: 870281-82-6;1146702-54-6
Molecular Formula: C22H18FN7O
5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone - Names and Identifiers
| Name | 5-Fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone |
| Synonyms | GS1101 CAL-101 Idelalisib CAL101,CAL-101 CAL-101 (GS-1101) Idelalisib(CAL-101) CAL-101 (Idelalisib, GS-1101) 5-Fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone 5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone 5-Fluoro-3-Phenyl-2-[(1S)-1-(9H-Purin-6-Ylamino)Propyl]-4(3H)-Quinazolinone (S)-2-(1-((9H-Purin-6-yl)aMino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
| CAS | 870281-82-6 1146702-54-6 |
| EINECS | 807-438-9 |
| InChI | InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28) |
5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone - Physico-chemical Properties
| Molecular Formula | C22H18FN7O |
| Molar Mass | 415.42 |
| Density | 1.47 |
| Melting Point | 250-252oC |
| Boling Point | 733.4±70.0 °C(Predicted) |
| Solubility | DMSO 83 mg/mL Water <1 mg/mL Ethanol 35 mg/mL |
| Appearance | White solid. |
| Color | White |
| pKa | 10.00±0.10(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| Use | A potent PI3K p110δ inhibitor |
| In vitro study | CAL-101 had little effect on p110α, p110β, and p110γ. CAL-101 acts on primary basophils to specifically block the CD63 expression regulated by fcO_c_c_r1 p110δ, with an EC50 of 8 nM. CAL-101 acts on B- cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) compared to acute myeloid leukemia (AML) and Myeloproliferative neoplasm (MPN) cells cells showed stronger activity. CAL-101 acts on SU-DHL-5, KARPAS-422 and CCRF-SB cells, reducing pAktS473, pAktT308, and the downstream target S6, EC50 of 0.1 to 1.0 μm. CAL-101 acts on CLL cells, inducing selective cytotoxicity, not through mutational status or interphase cytogenetics, but primarily through a caspase-dependent mechanism. Compared with normal B cells, CAL-101 preferentially produces cytotoxicity on CLL cells, and compared with LY294002, it does not produce toxicity on other hematopoietic cells. CAL-101 act on T cells and natural killer cells lack direct cytotoxic potential. CAL-101 inhibits the production of inflammatory cytokines, such as IL-6, IL-10, TNF-alpha, and IFN-gamma, and activates induced cytokines, such as CD40L. CAL-101 also resisted CD40L regulated CLL cell survival. CAL-101 acts on L1236 and L591 cells to induce cell accumulation in G1 phase and decrease in S phase, indicating that CAL-101 can be used as a new strategy for the treatment of Hodgkin's lymphoma (HL). |
5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone - Risk and Safety
| HS Code | 29399990 |
5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone - Introduction
CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM; The selectivity of p110δ acting on p110δ is 40 to 300 times higher than that of p110α/β/γ, and the selectivity of p110δ acting on p110δ is 400 to 4000 times higher than that of C2β, hVPS34, DNA-PK and mTOR. Phase 3.
Last Update：2022-10-16 17:29:30
5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone - Reference Information
| edelaris | idelalisib is a highly selective, orally potent phosphoinositide 3-kinase delta(PI3K-delta) inhibitor. PI3K-delta signaling is essential for B lymphocyte activation, proliferation, survival, migration, and is overactive in a variety of B cell malignancies. Currently, giglid is developing idelalisib as a single agent and in combination with a number of approved therapies and experimental therapies to investigate the treatment of different types of blood cancers. edularis tablets were developed by the United States in Gilead Sciences and approved by FDA in July 2014. Zydelig is a kinase inhibitor, suitable for relapsed chronic lymphocytic leukemia (CLL), treatment of relapsed follicular B- cell non-Hodgkin's lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL). |
| biological activity | Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with an IC50 of 2.5 nM in a cell-free assay; the selectivity for p110δ was 40 to 300 times that for p110α/β/γ, and 400 to 4000 times that for C2β, HVPS 34,DNA-PK and mTOR. Idelalisib can also induce autophagy. |
| Target | Value |
| p110δ (Cell-free assay) | 2.5 nM |
| p110γ (Cell-free assay) | 89 nM |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 21:11:58
![5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone](http://res.chembk.com/assets/images/structure/311364.gif)
Supplier List
Multiple Specifications
Product Name: CAL-101 Visit Supplier Webpage Request for quotationCAS: 870281-82-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple Specifications
Product Name: CAL-101 Visit Supplier Webpage Request for quotationCAS: 870281-82-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History